HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.8%

Neg 0% Neu 86.8% Pos 0%

HC Wainwright & Co. analyst Matthew Keller reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $31 price target.